Early protection events in swine immunized with an experimental live attenuated classical swine fever marker vaccine, FlagT4G

PLoS One. 2017 May 24;12(5):e0177433. doi: 10.1371/journal.pone.0177433. eCollection 2017.

Abstract

Prophylactic vaccination using live attenuated classical swine fever (CSF) vaccines has been a very effective method to control the disease in endemic regions and during outbreaks in previously disease-free areas. These vaccines confer effective protection against the disease at early times post-vaccination although the mechanisms mediating the protection are poorly characterized. Here we present the events occurring after the administration of our in-house developed live attenuated marker vaccine, FlagT4Gv. We previously reported that FlagT4Gv intramuscular (IM) administered conferred effective protection against intranasal challenge with virulent CSFV (BICv) as early as 7 days post-vaccination. Here we report that FlagT4Gv is able to induce protection against disease as early as three days post-vaccination. Immunohistochemical testing of tissues from FlagT4Gv-inoculated animals showed that tonsils were colonized by the vaccine virus by day 3 post-inoculation. There was a complete absence of BICv in tonsils of FlagT4Gv-inoculated animals which had been intranasal (IN) challenged with BICv 3 days after FlagT4Gv infection, confirming that FlagT4Gv inoculation confers sterile immunity. Analysis of systemic levels of 19 different cytokines in vaccinated animals demonstrated an increase of IFN-α three days after FlagT4Gv inoculation compared with mock infected controls.

MeSH terms

  • Animals
  • Classical Swine Fever / immunology*
  • Classical Swine Fever / prevention & control*
  • Classical Swine Fever / virology
  • Classical Swine Fever Virus / immunology*
  • Classical Swine Fever Virus / pathogenicity
  • Classical Swine Fever Virus / physiology
  • Cytokines / blood
  • Female
  • Interferon-alpha / blood
  • Palatine Tonsil / immunology
  • Palatine Tonsil / virology
  • Sus scrofa
  • Swine
  • Time Factors
  • Vaccines, Attenuated / pharmacology
  • Vaccines, Marker / pharmacology
  • Viral Vaccines / pharmacology*
  • Virus Replication

Substances

  • Cytokines
  • Interferon-alpha
  • Vaccines, Attenuated
  • Vaccines, Marker
  • Viral Vaccines

Grants and funding

This project was partially funded through the State of Kansas National Bio and Agro-Defense Facility Fund (NBAF) and Institute for Infectious Animal Diseases (IIAD) Career Development Program. We also thank ARS/USDA-University of Connecticut SCA# 58-1940-1-190 for partially supporting this work. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.